HB 703-FN (2006): relative to advertisement of prescription drugs and establishing the pharmaceutical marketing disclosure law.
Cite this page
Granite Record indexes the General Court’s record; it is not that record. Where a citation allows only one source, cite the General Court — every page here links to what it is drawn from. The date below is the day the page was read.
- MLA
- “HB 703-FN (2006): relative to advertisement of prescription drugs and establishing the pharmaceutical marketing disclosure law.” Granite Record, https://graniterecord.org/bill/2006/hb703. Accessed 24 Oct. 2026.
- APA
- Granite Record. (n.d.). HB 703-FN (2006): relative to advertisement of prescription drugs and establishing the pharmaceutical marketing disclosure law. Retrieved 24 Oct. 2026, from https://graniterecord.org/bill/2006/hb703
- Chicago
- Granite Record. “HB 703-FN (2006): relative to advertisement of prescription drugs and establishing the pharmaceutical marketing disclosure law.” Accessed 24 Oct. 2026. https://graniterecord.org/bill/2006/hb703.
- BibTeX
@misc{bill-2006-hb703, title = {HB 703-FN (2006): relative to advertisement of prescription drugs and establishing the pharmaceutical marketing disclosure law.}, howpublished = {Granite Record}, url = {https://graniterecord.org/bill/2006/hb703}, note = {Accessed 24 Oct. 2026} }
HB 703-FN (2006)
relative to advertisement of prescription drugs and establishing the pharmaceutical marketing disclosure law.
- Status: Killed
- Term: 2005-2006
- House committee: Commerce
- Subject: Miscellaneous
The Story
It was introduced on January 26, 2005 and referred to the House Commerce committee. The committee held a public hearing on February 22, 2005. The committee held a work session on March 16, 2005. The committee retained the bill, holding it for further work rather than reporting it out this year. The committee held a work session on September 21, 2005. The committee voted 15–4 to recommend that the House kill it, and the report was placed on the regular calendar. On January 4, 2006 the House voted to kill it on a division vote 264–96.
Sponsors
- Rep. John DeJoie (D - Merr 11) (prime sponsor)
- Rep. Judson Dexter (R - Ches 6)
- Rep. James Pilliod (R - Belk 5)
- Rep. Matt Quandt (R - Rock 13)
- Sen. Robert Letourneau (R - SD19)
- Sen. Lou D'Allesandro (D - SD20)
- Sen. Sylvia Larsen (D - SD15)
Hearings and Sessions
- February 22, 2005, 2:30 PM: hearing, House Commerce, RM302,LOB
- March 16, 2005, 2:30 PM: subcommittee work session, House Commerce, RM302,LOB <Rep Langley>
- September 21, 2005, 10:00 AM: subcommittee work session, House Commerce, RM302,LOB <Rep J Martin>
Votes
- January 4, 2006, House: Inexpedient to Legislate — yeas 264, nays 96, passed
The Docket
- January 26, 2005: Introduced and ref to Commerce
- February 22, 2005: Hearing Feb 22 2:30 RM302,LOB
- February 23, 2005: (Subcom: Reps Langley, Kathleen Taylor & Headd)
- March 16, 2005: Subcommittee Work Session Mar 16 2:30 RM302,LOB <Rep Langley>
- March 22, 2005: Retained in committee
- September 21, 2005: Ret Subcommittee Work Session Sep 21 10:00 RM302,LOB <Rep J Martin>
- November 30, 2005: Comm Report for Jan 4, 2006; ITL (vote 15-4; RC)
- January 4, 2006: ITL MA DIV 264-96
Laws It Would Change
Related Bills
- SB 61 (2007): relative to pharmaceutical marketers.
- SB 211-FN (2006): relative to pharmaceutical marketers.